|By mouth (chewables)|
|Bioavailability||74% (Tmax = 2–4 hours)|
|Elimination half-life||14 hours|
|Excretion||Biliary (major route)|
|Chemical and physical data|
|Molar mass||625.88 g·mol−1|
|3D model (JSmol)|
Afoxolaner (INN) is an insecticide and acaricide used in dogs. It is indicated for the treatment and prevention of flea infestations, and the treatment and control of tick infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds (~1.8 kilograms) of body weight or greater. It is given once a month.
Unlike most other flea treatments which are applied topically to the animal's coat, afoxolaner is administered orally in meat-flavoured tablets, and poisons fleas once they start feeding. It is used either alone or as a combination treatment with milbemycin oxime.
The US FDA reports that drugs in this class (isoxazolines) can have adverse neurologic effects on some dogs, such as muscle tremors, ataxia, and seizures.
- "Frontline NexGard (afoxolaner) for the Treatment and Prophylaxis of Ectoparasitic Diseases in Dogs. Full Prescribing Information" (PDF) (in Russian). Sanofi Russia. Retrieved 14 November 2016.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 70" (PDF). World Health Organization. pp. 276–7. Retrieved 14 November 2016.
- "NexGard (afoxolaner) Chewables. Full Prescribing Information" (PDF). Frontline Vet Labs, a Division of Merial, Inc. Duluth, GA 30096-4640 USA. Retrieved 14 November 2016.
- Shoop, WL; Hartline, EJ; Gould, BR; Waddell, ME; McDowell, RG; Kinney, JB; Lahm, GP; Long, JK; Xu, M; Wagerle, T; Jones, GS; Dietrich, RF; Cordova, D; Schroeder, ME; Rhoades, DF; Benner, EA; Confalone, PN (2 April 2014). "Discovery and Mode of Action of Afoxolaner, a New Isoxazoline Parasiticide for Dogs" (PDF). Veterinary Parasitology. 201 (3–4): 179–89. doi:10.1016/j.vetpar.2014.02.020. PMID 24631502. Retrieved 14 November 2016.
- Beugnet, F; deVos, C; Liebenberg, J; Halos, L; Fourie, J (25 August 2014). "Afoxolaner Against Fleas: Immediate Efficacy and Resultant Mortality After Short Exposure on Dogs" (PDF). Parasite. 21: 42. doi:10.1051/parasite/2014045. PMC 4141545. PMID 25148564. Retrieved 14 November 2016.
- Beugnet, F; Crafford, D; de Vos, C; Kok, D; Larsen, D; Fourie, J (15 August 2016). "Evaluation of the Efficacy of Monthly Oral Administration of Afoxolaner plus Milbemycin Oxime (NexGard Spectra®, Merial) in the Prevention of Adult Spirocerca lupi Establishment in Experimentally Infected Dogs" (PDF). Veterinary Parasitology. 226: 150–61. doi:10.1016/j.vetpar.2016.07.002. PMID 27514901. Retrieved 14 November 2016.
- Medicine, Center for Veterinary. "CVM Updates - Animal Drug Safety Communication: FDA Alerts Pet Owners and Veterinarians About Potential for Neurologic Adverse Events Associated with Certain Flea and Tick Products". www.fda.gov. Retrieved 2018-09-22.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|